Cary J. Claiborne - May 23, 2023 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Role
Chief Executive Officer, Director
Signature
/s/ Cary J. Claiborne
Stock symbol
ADIL
Transactions as of
May 23, 2023
Transactions value $
$0
Form type
4
Date filed
5/25/2023, 04:36 PM
Previous filing
Sep 20, 2022
Next filing
Jan 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADIL Common Stock Award $0 +420K +38.18% $0.00 1.52M May 23, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADIL Stock Option (Right to Buy) Award $0 +300K $0.00 300K May 23, 2023 Common Stock 300K $0.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023.